About this event

  • Date and time Thu 10 Oct 2019 from 9:00am to 5:00pm
  • Location Royal Society of Medicine
  • Organised by Nephrology

This conference brings together international experts and investigators to provide key updates on developments and discuss ongoing research and future strategies in acute kidney injury (AKI).

This year there will be a sharp focus on cutting edge scientific and clinical research, best practice, new treatments, prevention and identification, and quality improvement, but will cover much more.

AKI Frontiers 2019 is a one-day symposium that covers the full range of AKI related areas, such as; recent developments in service improvement, innovation, translational research, clinical trials and epidemiology.

AKI Frontiers will bring together a varied audience from academics to clinicians with an interest in AKI from across the healthcare spectrum to the historical setting of the RSM.

Topics include:

  • The pathophysiology of AKI
  • New potential treatments for AKI
  • How to prevent AKI

We would like to thank our exhibitor(s):

BioPorto, Kidney Research UK and NIHR Leeds MIC

Please note that none of the companies listed have had any influence or involvement over the agenda, content or organisation of this meeting.

Key speakers

Dr Sean Bagshaw

Dr Sean Bagshaw

Professor and Chair, Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Canada

Speaker's biography

Dr Bagshaw is a professor and chair, of the department of critical care medicine, faculty of medicine and dentistry, at the University of Alberta. He trained at the University of Calgary (internal medicine, critical care medicine, master of science epidemiology) and the Austin Hospital (critical care nephrology) in Melbourne, Australia.


Dr Bagshaw is supported by a Canada Research Chair in critical care nephrology. he has research expertise in clinical epidemiology, clinical trials and health services research. His research focuses on acute kidney injury, vulnerable populations (e.g., elderly, frail), intensive care unit organization and capacity. He has published over 350 peer-reviewed papers, numerous book chapters, and peer-reviewed for over 30 medical journals. Dr Bagshaw is a member of several organizations including the Canadian Critical Care Society, Canadian Critical Care Trials Group, and the Acute Disease Quality Initiative.

Dr Emmanuel de Almeida Burdmann

Dr Emmanuel de Almeida Burdmann

Associate Professor, Division of Nephrology, Department of Internal Medicine, University of São Paulo Medical School, Brazil

Speaker's biography

Dr Emmanuel A. Burdmann is associate professor in the division of nephrology, department of internal medicine, at the University of São Paulo Medical School, Brazil. He obtained his medical and PhD. degree from the University of São Paulo, where he also completed his fellowship. He did his post-doctoral fellowship with Professor William Bennett at the Oregon Health Sciences University. The member of numerous scientific societies, he is the past-president of both the Latin American Society of Nephrology and Hypertension and the Brazilian Society of Nephrology, and has served on the council of the International Society of Nephrology, the Kidney Disease Improving Global Outcomes (KDIGO®) executive committee and acted as a co-director of the 0by25 Program of the International Society of Nephrology.


Dr Burdmann was involved in the development of the KDIGO® clinical practice guidelines on acute kidney injury, is an editorial board member for several journals including the Brazilian Journal of Nephrology, Kidney International, PLOs One and American Journal of Kidney Diseases, and is the author or co-author of over 200 journal articles and book chapters.

Professor Patrick Murray

Professor Patrick Murray

Full Professor of Clinical Pharmacology, and Consultant Physician, University College Dublin School of Medicine

Speaker's biography

Patrick Murray is a full professor of clinical pharmacology in University College Dublin (UCD), and a consultant physician (clinical pharmacologist and nephrologist) in Dublin, Ireland. He received his medical education at UCD. Following his internship at the Mater Misericordiae University Hospital (MMUH), he completed a residency in internal medicine at Hennepin County Medical Center in Minneapolis, USA. He completed fellowship training programs in nephrology, critical care medicine, and clinical pharmacology at the University of Chicago Hospitals (UCH), USA. He practised as an intensivist, nephrologist, and clinical pharmacologist at UCH from 1996–2008, and was a professor at the University of Chicago Pritzker School of Medicine. He served as the fellowship training program director in nephrology, also directing the Acute Dialysis Service. He has a longstanding interest in research and education to improve the prevention, diagnosis, and therapy of acute kidney injury (AKI) and nephrotoxicity, and the pharmacotherapy of patients with kidney disease. He is a member of several international consensus groups that have produced guidelines for research and practice in the field of AKI (Acute Dialysis Quality Initiative (ADQI), Acute Kidney Injury Network (AKIN), Kidney Disease Outcomes Quality Initiative (KDOQI)).


Since 2008, he has been the inaugural professor of clinical pharmacology at UCD, and a consultant in nephrology and clinical pharmacology at MMUH and at St. Vincent’s University Hospital. He is chair of the MMUH drugs and therapeutics committee. He is the clinical director of the UCD Clinical Research Centre. In 2012, he was appointed the director of the Dublin Centre for Clinical Research (DCCR) Consortium Network, and also the clinical director of the Irish Clinical Research Infrastructure Network (ICRIN). From December 2012 through June 2018, he served as the dean and head of the School of Medicine at UCD.

Dr. F. Perry Wilson

Dr F. Perry Wilson, MD MSCE

Associate Professor of Medicine, Yale University School of Medicine

Speaker's biography

Dr Wilson grew up in Connecticut, before attending Harvard College where he graduated with a degree in biochemistry. He then attended medical school at Columbia College of Physicians and Surgeons, before completing his internship, residency, and fellowship at the University of Pennsylvania. In 2012, he received a masters degree in clinical epidemiology, which has informed his research ever since. At Yale since 2014, his goal is use patient-level data and advanced analytics to personalize medicine to each individual patient.

Dr Wilson uses epidemiologic and translational research methods to characterize predictors of outcomes in patients with both chronic kidney disease and acute kidney injury. In addition, he uses advanced machine-learning techniques to identify which patients are most likely to respond to a given intervention. These models can reduce the number of individuals exposed to a drug or intervention unnecessarily, reducing adverse events, and lowering costs.


View the programme

Registration, tea and coffee
Welcome and introduction

Dr Chris Laing, Consultant Nephrologist University College London Hospitals NHS Foundation Trust and Royal Free London NHS Foundation Trust, Honorary Associate Professor, University College London and Dr Andy Lewington, Consultant Nephrologist and Associate Professor, The Leeds Teaching hospitals NHS Trust

Session one: Special communications

Update on UK Kidney Research Consortium AKI Clinical Study Group

Dr Nicholas Selby, Associate Professor of Nephrology, University of Nottingham

Towards an international consensus of quality indicators in AKI care: Report from the ADQI consensus working group

Dr Andy Lewington

Kidney health inequalities in the UK – an agenda for change

Ms Sandra Currie, Chief Executive, Kidney Research UK

Why improving outcomes in AKI is a strategic national priority

Professor Steve Powis, Medical Director, NHS England

Panel discussion
Tea and coffee break

Session two: Rapid communications

Chairs: Ms Elaine Davies, Director of Research Operations, Kidney Research UK and Dr  F. Perry Wilson, MD MSCE, Associate Professor of Medicine, Yale University School of Medicine

Outcomes from recent clinical trials in AKI-vasculitis

Dr Ruth Pepper, Consultant Nephrologist, Royal Free London NHS Trust and Associate Professor, University College London

Recent developments in understanding the pathogenesis of AKI-sepsis

Dr Marlies Ostermann, Consultant in Critical Care and Nephrology, Guy’s and St Thomas NHS Foundation Trust

How do we optimise outcomes for patients with AKI-myeloma

Professor Paul Cockwell, Consultant Nephrologist, Queen Elizabeth Hospital Birmingham, 

Understanding chronic kidney disease (CKD) outcomes after AKI: Results of the AKI risk in Derby (ARID) study

Dr Kerry Horne, Specialty Trainee, Renal Medicine, University Hospitals of Derby and Burton NHS Foundation Trust

The prevention of postoperative AKI: An update

Dr John Prowle, Clinical Senior Lecturer, Intensive Care Medicine, Barts and the London School of Medicine and Dentistry

Panel discussion

Session three: Special communications

Strategies for fluid therapy in AKI prevention and care: Interpreting outcomes from recent trials and next steps

Dr Sean Bagshaw, Professor and Chair, Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Canada

AKI in South America: What have learned and next steps in improving outcomes

Dr Emmanuel de Almeida Burdmann, Associate Professor, Division of Nephrology, Department of Internal Medicine, University of São Paulo Medical School, Brazil

Improving AKI care through data science and digital health interventions

Dr  F. Perry Wilson

Panel discussion
Tea and coffee break

Session four: Special communications

Chairs: Dr Chris Laing and Dr Andy Lewington

The management of AKI in critical illness: Recent developments and future horizons

Dr Sean Bagshaw

Using deep learning AI to predict future AKI: results of the DeepMind-VA collaboration

Dr Chris Laing

The Shaun Summers memorial lecture

The utility of biomarkers in AKI prediction care: Where are we now?

Professor Patrick Murray, Full Professor of Clinical Pharmacology, and Consultant Physician, University College Dublin School of Medicine

Panel discussion
Closing remarks

Dr Chris Laing and Dr Andy Lewington



Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom